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Transgenic plants present enormous potential as a cost-effective and safe platform for large-scale
production of vaccines and other therapeutic proteins. A number of different technologies are under
development for the production of pharmaceutical proteins from plant tissues. One method used to
express high levels of protein in plants involves the employment of plant virus expression vectors. Plant
virus vectors have been designed to carry vaccine epitopes as well as full therapeutic proteins such as
monoclonal antibodies in plant tissue both safely and effectively. Biopharmaceuticals such as these
offer enormous potential on many levels, from providing relief to those who have little access to
modern medicine, to playing an active role in the battle against cancer. This review describes the
current design and status of plant virus expression vectors used as production platforms for
biopharmaceutical proteins.
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It is a sad fact that a leading cause of infant mortality in
developing countries continues to be from infectious diseases
which are quite preventable. New technologies which can both
deliver vaccines en mass and without the need for syringes, as
well as induce a strong mucosal immune response, could revolu-
tionize the accessibility of much needed vaccines in developing
countries. Approaches range from the use of inhalation devices
which deliver the vaccine antigen in the form of an aerosol spray,
to patches containing microneedles which can deliver the desiredll rights reserved.vaccine antigen across the skin barrier. A third tactic involves the
development of plant production platforms as delivery systems
for oral vaccines.
Plant-made vaccines have the potential to enhance vaccine
coverage in children and infants, particularly in resource-poor
regions where infectious diseases remain a problem (Rybicki,
2009, Yusibov et al., 2011). Plants have the advantage of being
capable of producing biopharmaceutical proteins that retain the
same structural integrity and activity as their mammalian-
derived counterparts. Plants expressing vaccine antigens can be
produced stably by means of transgenic plant technologies, or
transiently by agroinﬁltration or infection using recombinant
virus expression vectors (Daniell et al., 2009, Penney et al.,
2011). Proteins can be produced in plants from constitutive
promoters, or alternatively, if the protein proves to be toxic to
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speciﬁc promoters can enable recombinant proteins to be stored
within plant seed such as corn or rice at ambient temperatures for
prolonged periods of time.
Plant virus expression vectors are particularly attractive as
they require no lengthy steps of plant transformation, yet they
can express substantial levels of the gene of interest on a massive
scale rapidly, often within a few days. This production level can
be easily scaled up if needed, by merely increasing the number of
host plants. Moreover, vaccine proteins produced in plants can be
puriﬁed using a few simple steps, or in some cases, require only
partial puriﬁcation (Boehm, 2007, Paul and Ma, 2011). These
properties make plant virus expression vectors feasible for use to
address infectious diseases in the Third World today.
Their rapidity and easy scalability make plant virus expression
vectors attractive candidates for other reasons besides providing
vaccines and therapeutic proteins to those who reside in devel-
oping countries. Production platforms based upon plant viruses
are now being used to generate vaccines to combat speciﬁc
cancers, to offset global pandemics such as H1N1 inﬂuenza, and
even to produce vaccines against potential biological warfare
agents. Objectives such as these together present a powerful
driving force towards the further advancement of plant viruses
as a technology to produce biopharmaceuticals in plants.
Plant viruses have also been developed as expression plat-
forms for the large-scale production of proteins for industrial,
pharmaceutical, veterinary, and agricultural uses (Desai et al.,
2010; Rybicki, 2010). This review highlights the current status of
vaccine and therapeutic protein production using plant virus
expression vectors. More recent developments regarding the
construction of vectors based on Tobacco mosaic virus, Potato
virus X, Cowpea mosaic virus and two Geminiviruses are
described, and examples of vaccines produced using these
approaches are discussed. The review concludes with an overlook
of the future of plant virus expression vectors for the production
of vaccine and therapeutic proteins in plants.Technology platforms used to produce vaccine proteins
in plants
Biopharmaceutical proteins have been expressed in plants using a
variety of approaches. One approach involves the stable transforma-
tion of plant cells which are regenerated into transgenic plants. Two
common methods by which to generate transgenic plants are
Agrobacterium-mediated transformation and biolistic delivery
(Daniell et al., 2009). Plant viruses have emerged as an alternative
to stable genetic transformation for the expression of foreign proteins
in plants (Yusibov et al., 2011). Neither approach can be considered to
be exclusively optimal for protein production, although plant virus
expression systems have a number of selective advantages for
industrial scale protein production. Transgenic plants have the
advantage of heritability for production of recombinant proteins;
however, yields can often be low. Transient expression using virus
vectors, on the other hand, can provide easy scalability, as well as
rapid and high expression of industrial levels of recombinant protein.
Furthermore, the more recent versions of virus vectors lack the ability
to become encapsidated or move from cell to cell, thus mitigating
biocontainment issues often associated with the use of transgenic
plants as production platforms. The small genomes of plant viruses
are also advantageous as they are easy for researchers to manipulate.
Moreover, infecting plants with modiﬁed viruses is a rapid process,
with predicted yields often achieved within a few days or a couple of
weeks, and higher yields obtained than what is generally expected
from stably transformed plants (Rybicki, 2010).Transient expression of vaccine proteins in plants
Plant virus expression vectors have been under further devel-
opment as robust and efﬁcient systems by which to produce
vaccine and therapeutic proteins. Two major plant RNA virus
expression vector systems have been engineered for the produc-
tion of immunogenic peptides and proteins in plants. These
include epitope presentation systems (short antigenic peptides
fused to the CP that are displayed on the surface of assembled
virus particles) and polypeptide expression systems (systems
which express the entire recombinant protein) (Yusibov et al.,
2011). Plant DNA viruses, such as geminiviruses, have also been
under exploration as potential protein expression platforms.
DNA virus vectors lack the size restrictions and issues with instability
that their RNA virus vector counterparts experience. Geminiviruses in
particular, with their broad host range, accumulate to extremely high
copy numbers in inoculated cells, resulting in greatly elevated levels
of gene expression (Chen et al., 2011).
Plant viruses which have been engineered to produce vaccines
and therapeutic proteins include Tobacco mosaic virus, Potato
virus X, Cucumber mosaic virus, Cowpea mosaic virus and Alfalfa
mosaic virus (Yusibov et al., 2011). Viruses such as these have
been used as vectors for the expression of recombinant proteins
for over two decades. Several biopharmaceutical proteins have
been expressed using vectors based on full-length plant virus
genomes (Can˜izares et al., 2005a; Koprowski and Yusibov, 2001;
Lomonossoff and Hamilton, 1999). Full-length virus vectors can
spread systemically within a plant and are readily transmitted to
new plants if scale-up is required. However, biocontainment can
be an issue for their use in certain circumstances. For example,
some plant viruses used as vectors can be transmitted mechani-
cally; others are transmitted by insect vectors. As a result, it is
paramount that precautions be taken to prevent the unwanted
spread of virus vectors to nontarget organisms. Viruses can be
engineered so that they lack the genes necessary to move from
cell to cell, be transmitted by insects to other plants or undergo
any unexpected recombination events that limit their usefulness
as expression vectors. Target plants harboring virus vectors can
also be separated from other crops via physical isolation, such as
being strictly housed within greenhouses or in cell culture.
The use of plant virus vectors is also inﬂuenced by insert size
and host range. For example, virus vectors which have been
engineered for epitope presentation frequently exhibit restric-
tions with respect to the actual size of an epitope which can be
effectively displayed on the surface of a virus particle without
disturbing capsid protein conformation and virus particle assem-
bly. Similarly, viruses which have been developed as polypeptide
expression systems are restricted with respect to insert size as a
result of difﬁculties with respect to encapsidation and/or genome
stability. To circumvent these problems, deconstructed or deleted
versions of plant virus-based expression systems have been under
development (Gils et al., 2005; Gleba et al., 2004). Deconstructed
versions of the RNA viruses Tobacco mosaic virus (TMV), Potato
virus X (PVX), and Cowpea mosaic virus (CPMV) RNA-2 as well as
the geminivirus Beet curly top virus (BCTV) have successfully
been used been used to produce a variety of proteins in plants
(Lim et al., 2010; Can˜izares et al., 2005b; Chung et al., 2011).Human and animal trials for plant-derived vaccines
Tobacco mosaic virus and potato virus X
Tobacco mosaic virus (TMV) and Potato virus X (PVX), are rod
shaped viruses with single-stranded RNA genomes, and have been
widely used as virus expression vectors for biopharmaceutical
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deconstructed vector format. Since the genome of TMV, for
example, is encapsidated by over 2000 copies of coat protein, it
represents an optimal epitope presentation system. However, due
to size limitations, only small epitopes can be incorporated on the
virus particle surface. Some vaccine epitopes which have been
expressed on TMV include antigens from Foot and Mouth Disease
Virus, HIV-1, malaria and rotavirus (Wigdorovitz et al., 1999;
Yusibov et al., 1999; Turpenet al., 1995). TMV has also been used
as a polypeptide presentation system. By incorporating an addi-
tional CP subgenomic promoter onto the virus genome, recombi-
nant TMV viruses can express both their own coat protein as well
as a protein of interest. TMV vectors utilized in this manner
express plasmodium antigen, a- trichosanthin, a tumor-derived
ScFv, bovine herpes virus-gD protein, major birch pollen antigen,
and human growth hormone (Gils et al., 2005; Pe´res-Filgueira
et al., 2003; Kumangai et al., 1993; Wagner et al., 2004; Webster
et al., 2009).
Both full length virus vectors and their deconstructed versions
can be delivered via agroinfection. Deconstructed vector strate-
gies have been employed using TMV and the results have been
enormously successful. The genome of TMV has been ‘decon-
structed’ into two separate modules, as depicted in Fig. 1. One
module contains the portions of the genome required for replica-
tion, while the other contains cassettes designed for insertion of
foreign genes. In this way, biopharmaceutical proteins can be
expressed at high levels in a viral replicon system in plants (Gleba
et al., 2004). A technique for transfecting plants with these
recombinant virus vector modules, known as ‘magnifection’,
was also established by Icon Genetics. Using the magnifection
approach, an Agrobacterium tumefaciens suspension could be
inﬁltrated into the intercellular space of all mature leaves of a
tobacco plant, resulting in virus infection that is more synchro-
nous and faster than systemic infection. Deconstructed versions
of TMV have been used to generate HPV E7 protein, as well as
Norwalk virus-like particles in plants (Noris et al., 2011; Santi
et al., 2008). Another example of the use of the deconstructed
virus system can be demonstrated with the L1 protein of canine
oral papillomavirus, which was expressed in transgenic tobacco
chloroplasts using a Potato virus X vector. The transgenic plants
used in this production system expressed a suppressor of gene
silencing, which was able to improve protein expression even
more (Azhakanandum et al., 2007). Similarly, Mallory et al.
(2002), coexpressed PVX-based ‘amplicons’ along with a viral
suppressor of gene silencing in transgenic tobacco lines, resulting
in greatly increased levels of transgene expression. CombinedP35S
Replicase
P35S
Replicase
Fig. 1. Schematic representation of deconstructed version of Tobacco mosaic virus (TM
production of active replicons in plants. Virus replicase, MP: movement protein, CP;
synthetase terminator. X refers to the site of recombination. The constructs are deliver
modules recombine at speciﬁc sites into the nucleus.transgene-virus systems such as these will not be discussed
further in this review.
TMV vectors have been used widely by other researchers. For
example, Lindbo (2007a), co-introduced a 35S driven TMV vector
as well as a version of a viral suppressor of RNA silencing into
plants, resulting in the production of high levels of protein
(between 600 and 1200 micrograms of recombinant protein per
gram of inﬁltrated tissue) within a week post infection. Another
TMV RNA based overexpression vector (TRBO) constructed by the
same author, which lacked the TMV CP gene coding sequence and
so was unable to form virus particles, possessed a higher agroin-
fection efﬁciency and produced up to 100 times more recombi-
nant protein than the suppressor of silencing-enhanced system
(Lindbo, 2007b).
In another example, a vaccine against the endemic disease
plague, derived from the causative bacterial agent Yersinia pestis,
has been developed using the deconstructed tobacco mosaic
virus-based system (Molina et al., 2004). Plague antigens that
were puriﬁed from the Icon genetics TMV-based deconstructed
system were used in animal trials and shown to generate
systemic immune responses as well as provide protection against
an aerosol challenge by virulent Y. pestis. (Santi et al., 2006).
Similarly, Saejung et al., (2007) expressed the envelope protein of
Dengue virus using a tobacco mosaic virus-based transient
expression system. Mice which were immunized intramuscularly
with envelope protein D2EIII induced an anti-Dengue virus anti-
body response that exhibited neutralizing activity against Dengue
type 2 virus. Production levels as great as 300 mg/kg leaf fresh
weight were determined for HBsAg expressed in the MagnICONTM
viral vector expression system; furthermore, these could self-
assemble into VLPs (Huang et al., 2008). As a ﬁnal example,
Webster et al., (2009) described the rapid expression of the
malarial antigen PyMSP4/5 in Nicotiana benthamiana leaves using
the same deconstructed tobacco mosaic virus-based expression
system outlined above. Not only were levels of malarial antigen
up to 10% of total soluble protein or 1–2 mg/g of fresh weight
produced; the antigen retained its immunogenicity following
long-term storage at ambient temperature within freeze-dried
leaves. Malaria-speciﬁc antibodies were observed in mice fed this
plant-derived malaria antigen along with a mucosal adjuvant,
demonstrating that large quantities of malaria vaccine can be
produced and stored using this TMV-based production system.
Deconstructed versions of TMV expression systems have
recently moved to the forefront of the up and coming discipline
of personalized medicine, including a potential treatment
for various forms of cancer. For example, deconstructed TMVTNos
MP CP
P35S
TNos
TNos
MP RS
RS GOI CP
X
V). (a) Full-length TMV expression vector. (b) Deconstructed expression vector for
coat protein RS: recombination site. P35S: CaMV 35S promoter, Tnos: nopaline
ed into plant cells via agroinfection; when a deconstructed virus is used, the two
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which to potentially combat diseases such as Non-Hodgkins
Lymphoma (NHL). The ﬁfth highest cause of death in North
America, NHL refers to a tumor disease involving degenerate
B-cells which multiply uncontrollably, accumulating in the lymph
nodes, bone marrow and other tissues. Degenerate B-cells of each
individual NHL patient express a unique idiotype, which can be
used as a tumor marker. These idiotypic regions derived from
tumor cells which have been isolated from individual patients can
be rapidly and inexpensively expressed in plants using a virus
expression vector agroinﬁltrated into tobacco leaves (Fig. 2). This
strategy enables the required amounts of lymphoma vaccine for
each patient to be expressed very rapidly and at low cost. Plant-
made vaccines against NHL could act as powerful short-term
therapy which could be administered immediately after diagnosis
to keep tumors in check (McCormick et al., 2008).
Alternatively, Musiychuk et al., 2007 have constructed a novel
‘launch vector’, composed of TMV-based expression vector
sequences that are harbored on the Agrobacterium binary vector
pBI121. Upon introduction into plant tissue, multiple ssDNA
copies of target sequences are released, a property based on the1.
2.
3.4.
5.
6.
Fig. 2. TMV based plant-derived vaccine for Non-Hodgkins Lymphoma. (1)
Proliferating B-cells expressing unique idiotype are isolated from patient with
NHL. (2) cDNA containing idiotypic region is cloned into a viral vector. (3) Viral
vector containing the idiotype cDNA is transformed into Agrobacterium. (4)
Agrobacterium harboring viral vector is inﬁltrated onto whole plants. (5) Plants
are harvested for vaccine protein containing idiotype. (6) Puriﬁed vaccine protein
is infected into original patient to elicit immune response to cells expressing
idiotype.
35S
512
ProC Helicase V
48/58K L
NTR
Gene of interest
RNA-1
RNA-2
Fig. 3. Transient expression vector based on CPMV RNA-2. (a) Genomic organization of
of vaccine proteins. This is the RNA that is inoculated into plants for transient gene exp
open reading frame, fused to gene of interest.presence of left and right border sequences of the binary vector.
The TMV vector sequences launched in this fashion have been
shown to generate 100 mg quantities of protein per kg of plant
tissue in less than a week. Vaccines against the oncogenic E7
protein of HPV, the H5N1 inﬂuenza virus HA and NA domains, and
the F1 and V antigens of Y. pestis have been effectively produced
using this launch vector system and were shown to be protective
using animal models (Massa et al., 2007; Mett et al., 2008;
Chichester et al., 2009).
Cowpea mosaic virus
A number of other plant RNA viruses have been investigated
extensively for their potential to produce biopharmaceutical
proteins. Cowpea mosaic virus (CPMV) has been developed for
the production of vaccine and therapeutic proteins in plants with
great success (Canizares et al., 2005a, 2005b). CPMV represents an
ideal candidate since it replicates well in host plants, is very
stable, and can easily be extracted and puriﬁed from plants.
Initially, CPMV was developed as an epitope presentation system.
CPMV capsid has been well studied; it is comprised of 60 subunits
each of both large (L) and small (S) coat protein subunits that are
arranged to form an icosahedral virus surrounding a bipartite RNA
genome. Exposed loops on the surface of the capsid protein have
been identiﬁed and several of these loops have been used as the
site of insertion of foreign peptides. Recombinant virus particles
expressing foreign epitope sequences have been demonstrated to
produce yields similar to that of wild type viruses, and many
epitopes displayed on the surface of CPMV have been able to
successfully elicit strong immune responses (Lomonossoff and
Hamilton, 1999).
CPMV has also been engineered to express the 2A protein of
Foot and Mouth Disease Virus, which acts as a catalytic peptide to
promote cleavage between the viral proteins and GFP. Foreign
proteins have been expressed as fusions with the CPMV coat
protein or movement protein, with the addition of an integral
proteolytic cleavage site to allow the target protein to be released
(Gopinath et al., 2000).
Replicating RNA virus-based expression systems offer several
drawbacks; they may intrinsically alter the host cell, causing
perturbations to the endomembrane system which could result in
variations in the quality of recombinant protein or in different
post-translational modiﬁcation patterns. In addition to this, RNA
virus- based replication has been associated with a higher rate of
accumulated mutations, due to the poor ﬁdelity of RNA-depen-
dent RNA polymerases (RdRp). Recently, a novel nonreplicating
expression system based on a disabled version of RNA-2 of CPMV
has been developed which involves positioning a gene of interestNos
pg Pro Polymerase
S
NTR
CPMV RNAs-1 and 2. (b) CPMV RNA-2 nonreplicating construct for high expression
ression. NTR: nontranslated regions, 512: nucleotide position of CPMV RNA-2 ﬁrst
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of RNA-2 (Fig. 3). Agrobacterium-mediated transient transforma-
tion is used to obtain high-level expression of the foreign gene of
interest in the absence of virus replication, a feature that makes
this system extremely advantageous (Sainsbury and Lomonossoff,
2008). Deletion of an in-frame initiation codon located upstream
of the main translation initiation site of RNA-2 resulted in a
massive increase in foreign protein accumulation. In fact, proteins
ranging in diversity from a full-size IgG to a self-assembling virus-
like particle could be expressed to high levels (10% and 20% of
total extractable protein, respectively) (Sainsbury et al., 2010a).
A CPMV non-replicating system was further shown to maintain
high quality of puriﬁed anti-HIV-1 antibody produced in plants
(Sainsbury et al., 2010b). More recently, a CPMV-derived expres-
sion vector was used to transiently express a chimeric Human
papillomavirus 16 L1 protein carrying the M2e epitope of inﬂu-
enza A virus in tobacco plants. The chimeric proteins were able to
assemble into higher order structures, including virus-like particles,
and react with anti-inﬂuenza antibodies, thus demonstrating the
potential of this system for vaccine production (Matic et al., 2011).Geminiviruses
Another system under development for the production of
plant-made biopharmaceuticals is the use of a small plant DNA
virus known as geminivirus. Geminiviruses, named for their
twinned capsid morphology, are characterized by a small genome
and a broad host range, and can replicate to extremely high copy
numbers in infected cells (Timmermans et al., 1994). A number of
geminiviruses have been used to express foreign proteins in
plants; two geminiviruses have been developed further using
the deconstructed vector strategy. Bean yellow dwarf virus
(BeYDV), a mastrevirus, has been engineered to express its
replication initiator protein (Rep) under independent promoter
control (Fig. 4). This approach has been used to produce a vaccine
against Staphlococcus Enterotoxin B (SEB), considered to be a
potential biowarfare agent, as well as antigens derived from
Hepatitis B virus, Norwalk virus, HIV and HPV (Hefferon and
Fan, 2004; Huang et al., 2009; Regnard et al., 2010). Monoclonal
antibodies against Ebola virus have also been created using thisLIR
SIR
MP
CP
Rep
RepA
intron
V1
V2C1
C2
35S
35S
Nos
Nos
Rep
Gene of interest
Fig. 4. Geminivirus expression vector constructed for expression of vaccine proteins.
(a) Genomic organization of Bean yellow mosaic virus. (b) Deconstructed expression
vector. LIR: long intergenic region, SIR: short intergenic region.technique (Huang et al., 2010). Beet curly top virus, (BCTV), a
curtovirus, has also been developed as a deconstructed gemini-
virus to express foreign proteins. In this instance, the authors
were able to demonstrate that accumulation of the protein of
interest could be further enhanced by co-delivering an additional
plasmid which expresses a strong viral suppressor of RNA silen-
cing (Kim et al., 2007).Conclusions: onwards and upwards for future
commercialization
Plant-derived vaccines can be produced in numerous settings,
including cell culture, open ﬁelds and under greenhouse condi-
tions. While variable soil and weather conditions can make
outdoor production difﬁcult, cell suspension systems and green-
houses offer more precisely controlled environments. Continuous
culture of plant cell lines or hairy root systems which are able to
secrete the speciﬁc protein product into the surrounding media
can reduce expensive downstream processing in an effective
manner (Penney et al., 2011; Boehm, 2007). Puriﬁcation from
plant tissues is in general more facile and economical than
standard puriﬁcation from their mammalian and bacterial coun-
terparts. The ﬁrst vaccine to gain regulatory approval and be
licensed is a poultry vaccine for Newcastle disease, produced from
a cell culture bioreactor system (Sparrow et al., 2007). A number
of other plant-derived therapeutic proteins are currently under-
going extensive clinical trials and are approaching market release.
Many of these new products incorporate plant virus vectors in the
form of deconstructed vector systems, making biopharmaceutical
protein production even more rapid and productive than ever. As
demonstrated in this review, plant virus expression vectors
provide a powerful tool for future biopharmaceutical protein
production and will offer alternative solutions ranging from
producing novel personalized medicines to combating future
pandemics, and of course, to protecting the world’s poor against
preventable infectious diseases.
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